FOXO1在肾癌组织和细胞中的表达及临床意义  

Expression and clinical value of FOXO1 in renal cell carcinoma tissues and cells

作　　者：周立斌 李星 李升 吴铁林[1] 龙慧民[1] Zhou Libin;Li Xing;Li Sheng;Wu Tielin;Long Huimin(Department of Urology,Ningbo City Medical Treatment Center Lihuili Hospital,Zhejiang Ningbo 315040,China)

机构地区：[1]宁波市医疗中心李惠利医院泌尿外科,浙江宁波315040

出　　处：《现代肿瘤医学》2019年第6期1016-1020,共5页Journal of Modern Oncology

基　　金：浙江省医药卫生科技计划项目(编号:2019KY603);宁波市自然基金(编号:2017A610186)

摘　　要：目的:探讨FOXO1在肾癌组织和细胞中的表达及其与肾癌发生发展的关系。方法:实时定量PCR和Western blot检测肾癌细胞中FOXO1 mRNA和蛋白的表达情况;免疫组化方法检测肾癌组织中FOXO1蛋白的表达;应用针对人FOXO1基因的小干扰RNA在体外转染769-P细胞; CCK8检测细胞增殖情况。结果:免疫组化结果显示透明细胞肾癌和乳头状细胞肾癌FOXO1的阳性率低于嫌色细胞肾癌(P <0.05); FOXO1蛋白的表达与透明细胞肾癌的分期、分级有关(P <0.05); 769-P细胞FOXO1 mRNA和蛋白表达水平高于786-O和Caki-1细胞;利用特异性的siRNA抑制FOXO1 m RNA和蛋白表达后,发现769-P细胞的增殖加快。结论:FOXO1表达下降与肾癌的分型和透明细胞肾癌的分期、分级有关,FOXO1可作为肾癌诊断和预后的标志物及治疗的靶点。Objective:To study FOXO1 in renal cell carcinoma (RCC) tissues and renal cell carcinoma cell lines and its relation with renal carcinogenesis. Methods:The expression levels of FOXO1 transcripts and protein in renal cell carcinoma cell lines were examined by quantitative Real-time PCR and Western blot.Immunohistochemistry was used to examined FOXO1 protein in renal cell carcinoma tissues.769-P cells were transfected with small interference RNA against human FOXO1 gene.CCK8 assay was used to estimate the cell growth. Results:The FOXO1 protein positive rates in clear cell RCC (ccRCC) and papillary RCC (pRCC) were lower than chromophobe RCC (chRCC)( P <0.05).The expression levels of FOXO1 mRNA and protein in 769-P cells were higher than those in 786-O and Caki-1 cells.After inhibiting the expression levels of FOXO1 mRNA and protein using specific siRNA,the growth of 769-P cells was increased. Conclusion:The decreased expression of FOXO1 had correlated not only with the subtypes of RCC but also with the stage and grade of ccRCC.FOXO1 may become a diagnostic and prognostic marker and a new target to therapy the renal cell carcinoma.

关 键 词：FOXO1 肾癌 肾癌细胞系 细胞增殖 

分 类 号：R737.11[医药卫生—肿瘤]